Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Urinary Bladder Neoplasms 1Stomach Neoplasms 1Salivary Gland Neoplasms 1Ovarian Neoplasms 1Muscle Invasive Bladder Cancer 1HER2-positive Metastatic Breast Cancer 1HER2-low Breast Cancer 1Cervical Cancer Recurrent 1Breast Neoplasms 1

Interventions

Docetaxel 11Cisplatin 11Biopsy 7Radiotherapy 6Immunohistochemistry 6Carboplatin 6pembrolizumab 5Radiotherapy, Intensity-Modulated 5Magnetic Resonance Spectroscopy 5Cetuximab 5Trastuzumab 4Paclitaxel 4Nivolumab 4Gemcitabine 4Chemotherapy, Adjuvant 4Capecitabine 4Surgical Procedures, Operative 3Specimen Handling 3Radiosurgery 3Ipilimumab 3Goserelin 3Fluorodeoxyglucose F18 3Everolimus 3Erlotinib Hydrochloride 3sacituzumab govitecan 2pyrotinib 2pertuzumab 2bicalutamide 2Taxes 2Sorafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Salivary Gland Neoplasms × RC48 antibody × Clear all
NCT05898373 2023-06-12

Vedicitumomab Alone or in Combination for the Treatment of Locally Advanced or Metastatic SDC

Peking Union Medical College

Phase 1/2 Not yet recruiting
120 enrolled
Head & Neck

Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡